Product
Sabizabulin
1 clinical trial
1 indication
Indication
Breast CancerClinical trial
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 InhibitorStatus: Withdrawn, Estimated PCD: 2024-03-30